Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Grothey

Showing results (161-170 of 304) with videos related to

Pageof 31
Sort By:
Journal of the National Cancer Institute|August 23, 2015
Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall SurvivalMing-Wen An, Xinxin Dong, Jeffrey Meyers, et al.
Therapeutic Advances in Medical Oncology|July 7, 2018
5-fluorouracil and cardiotoxicity: a reviewJaskanwal D Sara, Jasvinder Kaur, Ryan Khodadadi, et al.
Cancer Treatment Reviews|July 30, 2015
Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancerJ Randolph Hecht, Jean-Yves Douillard, Lee Schwartzberg, et al.
The Oncologist|March 2, 2021
Use of Molecular Assays and Circulating Tumor DNA in Early-Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert GroupArturo Loaiza-Bonilla, Al B Benson, Axel Grothey, et al.
Clinical Colorectal Cancer|November 7, 2018
Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or CapecitabineSakti Chakrabarti, Jaskanwal Sara, Ronstan Lobo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2007
End points in advanced colon cancer clinical trials: a review and proposalCarmen Allegra, Charles Blanke, Marc Buyse, et al.
SOJ Anesthesiology & Pain Management|November 4, 2015
Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 PatientsHeshan Liu, Angelina D Tan, Rui Qin, et al.
Frontiers in Oncology|March 7, 2019
Impact of Tumor Location and Variables Associated With Overall Survival in Patients With Colorectal Cancer: A Mayo Clinic Colon and Rectal Cancer Registry StudyCassia B Wang, Faisal Shahjehan, Amit Merchea, et al.
The Oncologist|September 15, 2017
Impact of Metastasectomy in the Multimodality Approach for <i>BRAF</i> V600E Metastatic Colorectal Cancer: The Mayo Clinic ExperienceBenny Johnson, Zhaohui Jin, Mark J Truty, et al.
BMC Cancer|July 15, 2016
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort studyPashtoon M Kasi, Daisuke Kotani, Michael Cecchini, et al.
Pageof 31

Showing results (161-170 of 304) with videos related to

Sort By:
Pageof 31
Journal of the National Cancer Institute|August 23, 2015
Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall SurvivalMing-Wen An, Xinxin Dong, Jeffrey Meyers, et al.
Therapeutic Advances in Medical Oncology|July 7, 2018
5-fluorouracil and cardiotoxicity: a reviewJaskanwal D Sara, Jasvinder Kaur, Ryan Khodadadi, et al.
Cancer Treatment Reviews|July 30, 2015
Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancerJ Randolph Hecht, Jean-Yves Douillard, Lee Schwartzberg, et al.
The Oncologist|March 2, 2021
Use of Molecular Assays and Circulating Tumor DNA in Early-Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert GroupArturo Loaiza-Bonilla, Al B Benson, Axel Grothey, et al.
Clinical Colorectal Cancer|November 7, 2018
Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or CapecitabineSakti Chakrabarti, Jaskanwal Sara, Ronstan Lobo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2007
End points in advanced colon cancer clinical trials: a review and proposalCarmen Allegra, Charles Blanke, Marc Buyse, et al.
SOJ Anesthesiology & Pain Management|November 4, 2015
Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 PatientsHeshan Liu, Angelina D Tan, Rui Qin, et al.
Frontiers in Oncology|March 7, 2019
Impact of Tumor Location and Variables Associated With Overall Survival in Patients With Colorectal Cancer: A Mayo Clinic Colon and Rectal Cancer Registry StudyCassia B Wang, Faisal Shahjehan, Amit Merchea, et al.
The Oncologist|September 15, 2017
Impact of Metastasectomy in the Multimodality Approach for <i>BRAF</i> V600E Metastatic Colorectal Cancer: The Mayo Clinic ExperienceBenny Johnson, Zhaohui Jin, Mark J Truty, et al.
BMC Cancer|July 15, 2016
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort studyPashtoon M Kasi, Daisuke Kotani, Michael Cecchini, et al.
Pageof 31